EFFECT OF SIMVASTATIN THERAPY UPON IMMUNOLOGICAL MARKERS OF ATHEROSCLEROSIS IN THE PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.15789/1563-0625-2011-1-101-104
Abstract
Аbstract. The study concerned in vitro effects of mevastatin, in”iximab, r-met-Hu-sTNF-RI and IL-1Ra upon antigen-induced activation of EBV-speciлc CD4+T-cells from peripheral blood of the patients with rheumatoid arthritis (RA). RA patients were shown to have signiлcantly lower contents of antigen-activated, EBV-speciлc CD4+T-cells than healthy donors. In healthy controls, mevastatin, in”iximab, r-met-Hu-sTNF-RI and IL-1Ra did not cause sufлcient changes in concentrations of CD4+, IFN-γ+ cells. Likewise, there was no detectable in”uence of the abovementioned drugs upon the numbers of RA EBV-speciлc CD4+ , IFNγ+ cells. Thus, in RA patients, the antigen-induced activation of EBVspeciлc CD4+T-cells is reduced. Meanwhile, in vitro supplement with statins and the mentioned biological agents did not promote further suppression of this cell activity. (Med. Immunol., 2011, vol. 13, N 1, pp 101-104)
About the Authors
I. V. Shirinsky
Российская академия медицинских наук Научно-исследовательского института клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
V. S. Shirinsky
Российская академия медицинских наук Научно-исследовательского института клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
References
1. Ширинский И.В., Желтова О.И., Ширинский В.С., Козлов В.А. Влияние симвастатина на активность болезни и содержание холестерина субфракций липопротеинов сыворотки крови у больных ревматоидным артритом // Терапевтический архив. – 2008. – № 3. – С. 63-65.
2. Насонов Е.Л. Иммунологические маркеры атеросклероза // Терапевтический архив. – 2002. – № 5. – С. 57-60.
3. Ребров А.П.,Воскобой И.П. Роль воспалительных и инфекционных факторов в развитии атеросклероза // Терапевтический архив. – 2004. – № 1. – С. 78-82.
4. Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А. Эффективность и безопасность симвастатина при ревматоидном артрите открытое контролируемое исследование // Медицинская иммунология. – 2007. – № 4-5. – С. 477-482.
5. Gabriel S.E. Cardiovascular morbidity and mortality in rheumatoid arthritis // Am. J. Med. – 2008. – Vol. 121. – P. 9-14.
6. Gabriel S.E., Crowson C.S., Kremers H.M., Doran M.F., Turesson C., O’Fallon W.M., Matteson E.L. Survival in rheumatoid arthritis: a populationbased analysis of trends over 40 years // Arthritis Rheum. – 2003. – Vol. 48. – P. 54-58.
7. Goodson N.J., Symmons D.P., Scott D.G., Bunn D., Lunt M., Silman A.J. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort // Arthritis Rheum. – 2005. – Vol. 52. – P. 2293-2299.
8. Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger W.H., Jr., Heimovitz H., Cohen H.J., Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly // Am. J. Med. – 1999. – Vol. 106. – P. 506-512.
9. Hedman A., Larsson P.T., Alam M., Wallen N.H., Nordlander R., Samad B.A. CRP, IL-6 and endothelin1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? // Int. J. Cardiol. – 2007. – Vol. 120. – P. 108-114.
10. Mazer S.P., Rabbani L.E. Evidence for Creactive protein’s role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP // J. Thromb. Thrombolysis. – 2004. – Vol. 17. – P. 95-105.
11. Nakou E.S., Liberopoulos E.N., Milionis H.J., Elisaf M.S. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview // Curr Vasc Pharmacol. – 2008. – Vol. 6. – P. 258-270.
12. Retterstol L., Eikvar L., Bohn M., Bakken A., Erikssen J., Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction – a 10 year follow-up study // Atherosclerosis. – 2002. – Vol. 160. – P. 433-440.
13. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men // Circulation. – 2000. – Vol. 101. – P. 1767-1772.
14. Rye K.A., Barter P.J. Antiinflammatory actions of HDL: a new insight // Arterioscler. Thromb. Vasc. Biol. – 2008. – Vol. 28. – P. 1890-1891.
15. Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. – 2009. – Vol. 38. – P. 23-27.
16. Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization // Stroke. – 2006. – Vol. 37. – P. 1923-1932.
17. van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? // Arthritis Rheum. – 2002. – Vol. 46. – P. 862-873.
18. van Gestel A.M., Prevoo M.L., van′t Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria // Arthritis Rheum. – 1996. –Vol. 39. – P. 34-40.
Review
For citations:
Shirinsky I.V., Shirinsky V.S. EFFECT OF SIMVASTATIN THERAPY UPON IMMUNOLOGICAL MARKERS OF ATHEROSCLEROSIS IN THE PATIENTS WITH RHEUMATOID ARTHRITIS. Medical Immunology (Russia). 2011;13(1):101-104. (In Russ.) https://doi.org/10.15789/1563-0625-2011-1-101-104
Views:
932
Email this article 